Mylan NV (NASDAQ: MYL) a United States-based generic and specialty pharmaceuticals company, and Fujifilm Kyowa Kirin Biologics Co Ltd, a company established by FUJIFILM Corporation and Kyowa Kirin Co Ltd, has received approval from the United States Food and Drug Administration (FDA) for its Hulio (adalimumab-fkjp), a biosimilar to AbbVie's Humira (adalimumab), intended for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis (four years and older), ankylosing spondylitis, adult Crohn's disease, psoriatic arthritis, ulcerative colitis and plaque psoriasis, offered in both prefilled syringe and auto-injector presentations, it was reported on Thursday.
The product's approval was based on a comprehensive analytical, preclinical and clinical program. Fujifilm Kyowa Kirin Biologics conducted the Phase three clinical study, ARABESC that indicated no clinically meaningful differences in terms of safety, efficacy and immunogenicity compared with the reference product, Humira, in rheumatoid arthritis patients.
Both firms collaborated in 2018 for the commercialisation of Hulio in Europe, and Mylan has commercialised the product in several countries across the region.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca